RDY Earnings Date: Jan 22, 2027 (Estimated) — Dr. Reddy's Laboratories Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is RDY's next earnings date?
Dr. Reddy's Laboratories Limited (RDY) is expected to report Q3 2027 earnings on Friday, January 22, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.15 on revenue of $1.00B.
How did RDY do in its last earnings report?
In its most recent report on Oct 23, 2026 (Q2 2027), Dr. Reddy's Laboratories Limited posted EPS of $0.12 versus the $0.10 estimate, a beat of 22.4%. Revenue was $913.3M against a $843.5M estimate. The stock's 1-day post-earnings move was -0.2%.
How much does RDY stock move after earnings?
RDY beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.0% (up or down) in the day after earnings.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
🤖 AI Earnings Analysis
Dr. Reddy’s delivered a modest $0.12 EPS beat versus $0.10, but earnings fell from $0.19 year over year, leaving specialty-generics performance mixed; missing revenue data limits confidence in growth quality.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | Q2 2027 | 0.10 | 0.12 | +22.45% | $913.3M | ✅ Beat | -0.15% | +6.65% | — |
| 2026-07-22 | Q1 2027 | 0.17 | 0.06 | -64.71% | $853.0M | ❌ Miss | -9.37% | -6.08% | -3.04% |
| 2026-05-12 | Q4 2026 | 0.09 | 0.03 | -67.78% | $821.8M | ❌ Miss | -5.20% | +3.52% | +1.22% |
| 2026-01-20 | Q3 2026 | 0.16 | 0.16 | +1.88% | $978.8M | ✅ Beat | +0.16% | +6.61% | +11.60% |
| 2025-10-24 | Q2 2026 | 0.18 | 0.19 | +5.56% | $992.0M | ✅ Beat | -0.28% | -7.98% | -4.88% |
| 2025-01-23 | Q3 2025 | 0.20 | 0.20 | +0.00% | $977.0M | ➖ Inline | -6.23% | -10.38% | -11.52% |
| 2024-11-05 | Q2 2025 | 0.20 | 0.18 | -10.00% | $957.0M | ❌ Miss | -1.30% | +1.37% | -4.10% |
| 2024-07-27 | Q1 2025 | 0.18 | 0.20 | +11.11% | $919.9M | ✅ Beat | +1.00% | +2.94% | +1.94% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2026 · $335.93B total · annual
| Segment | Share | Revenue | YoY | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
| Others Countries Country | 35.3% | $118.72B | +25.8% | $49.58B | $60.95B | $68.96B | $67.47B |
| UNITED STATES | 35.1% | $117.89B | -21.1% | — | — | — | — |
| India Country | 19.2% | $64.54B | +15.6% | $32.09B | $36.25B | $43.99B | $50.50B |
| Russia Country | 10.4% | $34.79B | +34.0% | $16.90B | $15.82B | $20.88B | $21.23B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.